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there appears to be a delicate balance of NO bioactivity
necessary for optimal cardiac performance after a car-
diac injury. 
Cardiopulmonary bypass (CPB) can be considered as
a form of inflammatory injury5 whose precise timing is
controlled and is associated with the release of pro-
inflammatory cytokines.6 Pro-inflammatory cytokines
N itric oxide (NO) is synthesized by the nitric oxidesynthase (NOS) family of isoenzymes, which con-
verts L-arginine to NO and L-citrulline.1 The roles of
constitutive NOS and inducible NOS (iNOS) in modu-
lating cardiac contractility have been recently re-
viewed.2 Either deficient3 or excessive4 generation of
NO appears to be detrimental to heart function. Thus
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in turn may induce iNOS and thereby impair cardiac
muscle performance.7 Although myocardial levels of
NO are increased after CPB,8 this increase has not been
previously ascribed to the action of iNOS. Therefore
we have tested whether the activity of iNOS is
increased after CPB and have further hypothesized that
administration of an NO donor might down-regulate
the resultant increased activity of iNOS.9,10 We have
tested the effects of the NO donor S-nitrosoglutathione
(GSNO) because it can inhibit blood cell activation at
doses lower than those required to elicit vasodilata-
tion11 and protect against an oxidative injury.12 Our
study shows that CPB leads to an increased activity of
iNOS and that this effect is inhibited by GSNO.
Methods
Animal preparation. These studies were carried out with
the approval of the University of Saskatchewan Animal Care
Committee. They are in compliance with the “Principles of
Laboratory Animal Care” formulated by the National Society
for Medical Research and the “Guide for the Care and Use of
Laboratory Animals” published by The National Institutes of
Health. Dogs were anesthetized with pentobarbital (15
mg/kg), intubated, and their lungs mechanically ventilated
(Respiratory Pump, model 607, Harvard Apparatus Co,
Dover, Mass). Anesthesia was maintained with a constant
infusion of pentobarbital (1.0 mg/kg per hour), morphine (0.1
mg/kg per hour), and vecuronium (0.1 mg/kg per hour). A
thermistor-tipped pulmonary artery catheter introduced
through the right external jugular vein was used to measure
mean pulmonary artery pressure, pulmonary capillary wedge
pressure, mean right atrial pressure, and cardiac output. A
catheter inserted through the femoral artery was used to mea-
sure mean systemic artery pressure and obtain blood samples
for arterial blood gas analysis. Vascular pressures were mea-
sured with disposal transducers (Cobe Laboratories, Inc,
Lakewood, Colo) and continuously displayed (Space Labs,
model 510, Squibb, Hollsboro, Ore).
To obtain wide surgical access, we performed bilateral
thoracotomies through the fifth intercostal spaces. Heparin
was administered (5000 U intravenously followed by 1000
units/h intravenously), and via the left atrial appendage a
noncompliant catheter (8F) was positioned in the left atrium
just above the mitral valve. This catheter was used to mea-
sure left atrial pressure, sample left atrial blood, and decom-
press the left ventricle during CPB. A balloon angioplasty
catheter (6F) was positioned just proximal to the aortic valve
via the right internal carotid artery and its position manually
confirmed. When the angioplasty catheter was inflated to its
maximal volume (10 mL) within the aorta, it produced the
equivalent of externally crossclamping the aorta. Before the
start of CPB, a cannula was inserted into the right atrium to
complete the bypass circuit. Arterial blood from the oxy-
Fig 1. Protocol followed by the 4 groups of dogs. Animals were randomized to receive cardiopulmonary bypass
(CPB-PLAC or CPB-GSNO) or to serve as control (CTRL-PLAC or CTRL-GSNO). 
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genator was returned to the animals through the femoral
artery catheter.
CPB was initiated with a membrane oxygenator (Capiox
Hollow Fiber Oxygenator, Terumo Corporation, Tokyo,
Japan) and a blood pump (Sarns model 5000 Console,
Sarns/3M, Ann Arbor, Mich) at a flow rate of 100 mL/kg.
Cold (7°C-8°C) cardioplegic solution was delivered ante-
gradely through the distal port of the aortic angioplasty
catheter and consisted of a mixture of saline solution/potassi-
um and blood in a 1:2 ratio. Five minutes after the initiation
of CPB, the aorta was occluded by inflation of the angioplas-
ty balloon. Blood cardioplegia (BCD4 Sharely, Anaheim,
Calif) was then commenced, initially at a KCl concentration
30 mEq/L and subsequently at a concentration to 10 mEq/L.
Cardioplegic solution with continuous surface cooling was
administered to eliminate electrical activity. The animals
were systemically cooled to 24°C over 10 minutes, and the
aortic balloon inflation was maintained for a further 50 min-
utes. Before the aortic balloon was deflated, 150 mL of warm
cardioplegic solution without KCl supplementation was
administered. In the animals receiving GSNO, an additional
dose of GSNO (1.5 m g/kg) was administered with the initial
and final cardioplegic solution. After deflation of the aortic
balloon, mechanical ventilation, which had been stopped dur-
ing CPB, was resumed and the animals were warmed to 37°C
over the subsequent 30 minutes. In this manner, total CPB
lasted for 90 minutes. Any blood collected within the thoracic
cavity was transfused into the CPB circuit. The dogs were
observed for a further 4 hours after cessation of CPB. During
this period systemic and right atrial pressures were main-
tained at more than 60 and between 5 and 15 mm Hg, respec-
tively. If systemic arterial pressure remained below 60 mm
Hg despite radial artery pressure being raised to 15 mm Hg
by a volume infusion, an infusion of phenylephrine was titrat-
ed for a systemic arterial pressure of more than 60 mm Hg.
Experimental groups. Fig 1 outlines our experimental
protocol. A total of 24 mongrel dogs (20-25 kg) were studied.
Twelve dogs were randomized to receive CPB and 12 were
randomized to serve as controls. Of the animals randomized
to CPB, 6 dogs were further randomized to receive a contin-
uous infusion of GSNO (CPB-GSNO) and 6 dogs received a
similar volume of placebo (CPB-PLAC). At higher doses
GSNO also exerts a vasodilator effect13; therefore, to deliver
a near maximal nonvasodilator dose of GSNO, we found the
dose of GSNO that decreased systemic arterial pressure by
10% below baseline values in each animal. This dose of
GSNO was then maintained at a constant infusion rate start-
ing just before the thoracotomies were performed and ending
30 minutes after the cessation of CPB. The GSNO infusion
was delivered through the proximal port of the pulmonary
artery catheter.
A similar protocol was followed in the remaining 12 dogs,
although they did not receive CPB. Six animals were ran-
domized to receive GSNO (CTRL-GSNO) and 6 were ran-
domized to receive placebo (CTRL-PLAC). All animals
received continuous anesthesia and followed a similar proto-
col to the CPB-treated animals, but they did not have thora-
cotomies performed and did not have the aortic, left atrial,
and right atrial lines inserted. The drug infusions (GSNO or
placebo) were given over times similar to those of the CPB-
treated animals. The animals were then observed for a further
4 hours and received infusions of normal saline solution to
match the same right atrial (5-15 mm Hg) and systemic arte-
rial pressures (>60 mm Hg) as the CPB-treated animals.
Sodium bicarbonate was infused during CPB as necessary to
maintain arterial pH between 7.3 and 7.45.
At the conclusion of the studies all 24 animals were killed
by a barbiturate overdose. Immediately after death, the heart
and lungs were rapidly removed. Biopsy sections (0.5 cm2)
from all 4 heart chambers and a 1-cm long portion of the prox-
imal left descending coronary artery were removed, frozen in
liquid nitrogen, and preserved for further analysis (see below).
Measurements and calculations. After insertion of all
catheters, baseline blood samples were obtained for measure-
ments of hemoglobin, white cell count, and differential.
Whole blood samples were also prepared for subsequent
analysis of granulocyte CD18 expression by flow cytometry
(see below). Arterial and mixed venous blood gases were
simultaneously obtained for measurement of blood gases and
oxyhemoglobin saturation. Mixed venous and arterial blood
gases were directly measured at 37°C with appropriately cal-
ibrated electrodes (CIBA Corning, model 238 pH Blood Gas
Analyzer, Medfield, Mass) and then corrected for core tem-
perature.14 Oxyhemoglobin saturation was measured (2500
Co-Oximeter, CIBA Corning), and then intrapulmonary shunt
could be calculated. Hemodynamic measurements included
cardiac output, systemic arterial pressure, pulmonary artery
pressure, pulmonary capillary wedge pressure, left atrial pres-
sure, and right atrial pressure. All measurements were repeat-
ed 1 hour and 4 hours after bypass. Measurements of systemic
and right atrial pressure were repeated as needed after bypass
to maintain our predetermined hemodynamic goals.
Neutrophil expression of CD11b and CD18 was assessed
with flow cytometry (FACScan, Becton Dickinson and
Company, San Jose, Calif). In brief, 1 mL of heparinized
blood was added to 14 mL of standard lysing solution (NH4Cl,
KHCO3, tetrasodium ethylenediaminetetraacetic acid adjusted
to pH 7.3). Cells were pelleted (1200 rpm for 5 minutes) and
resuspended in ice-cold phosphate-buffered saline solution
containing 0.1% bovine serum albumin and 0.01% sodium
azide. Cell labeling procedures were conducted with this same
solution, and cells were maintained at 4°C throughout the pro-
cedure. Cells were reacted with either an irrelevant, isotype-
matched fluorescein isothiocyanate–conjugated rat monoclon-
al antibody (MCA1125F) (Serotech Ltd, Oxford, United
Kingdom) or fluorescein isothiocyanate–conjugated rat anti-
human CD18 (MCA503F; Serotech) that cross-reacted with
canine CD18. Cells were then washed 3 times and fixed in 2%
paraformaldehyde. Flow cytometric analyses were performed
24 to 48 hours after cells were labeled, and the analysis was
restricted to neutrophils on the basis of forward-angle light
scatter and right-angle light scatter. The mean fluorescent
intensity of CD18 labeling was used as a measure of CD18
expression. 
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For the measurement of NOS activity, tissue samples were
homogenized in a homogenization buffer (tromethamine 50
mmol/L, sucrose 320 mmol/L, dithiothreitol 1 mmol/L, leu-
peptin 10 m g/mL, soybean trypsin inhibitor 10 m g/mL, and
aprotinin 2 m g/mL) by sonication and centrifuged (10,000g,
20 minutes, 4°C). The resultant supernatant was assayed for
NOS activity as described.15 In brief, tissue aliquots were
incubated with L[U-14C]-arginine (Nycomed Amersham,
Buckinghamshire, United Kingdom) for 20 minutes at 37°C
in a potassium phosphate buffer containing the following:
reduced nicotinamide adenine dinucleotide, 0.1 mmol/L;
tetrahydrobiopterin, 0.01 mmol/L; MgCl2, 1 mmol/L; CaCL2,
0.24 mmol/L; and L-arginine, 20 m mol/L. NG-monomethyl-L-
arginine (1 mmol/L), an inhibitor of NOS, was used to deter-
mine NOS-dependent L-citrulline formation as an index of
enzyme activity. A Ca2+-chelating agent (ethyleneguano-
sinetetraacetic acid, 1 mmol/L) was used to differentiate
between Ca2+-dependent and -independent NOS activities of
enzymes that were expressed as picomoles per minute per
milligram of protein.
Statistics. Data were compared between period and groups
with a 1-way or 2-way analysis of variance as appropriate,
and when the F statistic showed a significant difference, a
Student-Newman-Keuls multiple comparison test was used to
determine specific group and period differences (SigmaStat,
Jandel Scientific, Corte Madera, Calif). We prospectively
decided to limit the number of comparisons and we a priori
selected to compare only within-group changes over time and
to compare only changes between CPB-PLAC with CPB-
GSNO groups and between CTRL-PLAC with CTRL-GSNO
groups. All values are shown as means ± SD. 
Table I. Selected hemodynamic values in all 4 groups 
Hemodynamic One hour Four hours 
value Baseline after bypass after bypass
Heart rate (beats/min)
CTRL-PLAC 100 ± 36 77 ± 28 82 ± 30
CTRL-GSNO 124 ± 30 101 ± 40 92 ± 52
CPB-PLAC 125 ± 29 130 ± 34 156 ± 16
CPB-GSNO 140 ± 29 146 ± 18 150 ± 14
PSA (mm Hg)
CTRL-PLAC 119 ± 20 111 ± 13 110 ± 15
CTRL-GSNO 110 ± 9 105 ± 13 100 ± 17
CPB-PLAC 138 ± 24 87 ± 15* 87 ± 22*
CPB-GSNO 106 ± 23 93 ± 15* 87 ± 18*
PRA (mm Hg)
CTRL-PLAC 5 ± 2 6 ± 1 6 ± 3
CTRL-GSNO 5 ± 2 6 ± 3 6 ± 3
CPB-PLAC 5 ± 2 7 ± 3 6 ± 3
CPB-GSNO 6 ± 2 6 ± 2 5 ± 2
PCWP (mm Hg)
CTRL-PLAC 9 ± 2 8 ± 2 8 ± 2
CTRL-GSNO 8 ± 2 8 ± 4 8 ± 3
CPB-PLAC 9 ± 3 9 ± 3 10 ± 4
CPB-GSNO 8 ± 3 8 ± 2 6 ± 2
SVR (dyne/s/cm5)
CTRL-PLAC 7708 ± 2306 8067 ± 1789 7731 ± 2451
CTRL-GSNO 6373 ± 1232 6654 ± 1885 6331 ±1214
CPB-PLAC 7787 ± 1890 7149 ± 2522 9522 ± 3309*
CPB-GSNO 5738 ± 2337 5507 ± 1822 9066 ± 2712*
PVR (dyne/s/cm5)
CTRL-PLAC 422 ± 181 415 ± 178 480 ± 241
CTRL-GSNO 472 ± 204 433 ± 179 437 ± 150
CPB-PLAC 454 ± 274 753 ± 256 963 ± 311
CPB-GSNO 457 ± 191* 517 ± 251 1156 ± 476
Cardiac output (L/min)
CTRL-PLAC 1.2 ± 0.2 1.3 ± 0.3 1.2 ± 0.3
CTRL-GSNO 1.4 ± 0.4 1.3 ± 0.6 1.3 ± 0.5
CPB-PLAC 1.4 ± 0.2 1.0 ± 0.4 0.7 ± 0.2*
CPB-GSNO 1.7 ± 0.9 1.5 ± 0.8 0.8 ± 0.2*
PSA, Mean systemic blood pressure; PRA, mean right atrial pressure; PCWP,
pulmonary capillary wedge pressure; SVR, systemic vascular resistance (cal-
culated as SVR = PSA – PRA/Cardiac output · 80); PVR, pulmonary vascular
resistance. 
*Denotes a significant difference (P < .05) compared with other periods with-
in the same group. 
Table II. Selected biochemical and hematologic val-
ues in all 4 groups 
Biochemical and One hour Four hours 
hematologic values Baseline after bypass after bypass
Hemoglobin (g/dL)
CTRL-PLAC 13.5 ± 1.6* 12.5 ± 1.7 12.3 ± 1.8
CTRL-GSNO 12.2 ± 1.5* 11.3 ± 1.1 11.2 ± 1.2
CPB-PLAC 12.4 ± 1.8* 7.2 ± 1.0 6.9 ± 0.9
CPB-GSNO 12.8 ± 0.8* 7.3 ± 0.7 7.7 ± 1.0
WBC count (109 cells)
CTRL-PLAC 8.1 ± 2.0 7.2 ± 1.2 7.7 ± 0.8
CTRL-GSNO 6.6 ± 2.3* 7.7 ± 2.6 8.6 ± 2.2
CPB-PLAC 5.3 ± 1.5 5.3 ± 1.7 6.9 ± 2.7*
CPB-GSNO 6.0 ± 1.4 5.4 ± 1.7 6.7 ± 1.7*
PO2 (mm Hg)
CTRL-PLAC 617 ± 24 599 ± 48 626 ± 18
CTRL-GSNO 634 ± 41 619 ± 31 615 ± 90
CPB-PLAC 483 ± 72 285 ± 197 294 ± 217
CPB-GSNO 456 ± 109 414 ± 118 483 ± 145
PCO2 (mm Hg)
CTRL-PLAC 32 ± 6 34 ± 7 39 ± 6*
CTRL-GSNO 36 ± 12* 39 ± 15 41 ± 13
CPB-PLAC 33 ± 10 29 ± 8 31 ± 10
CPB-GSNO 30 ± 11 35 ± 12 34 ± 10
pH
CTRL-PLAC 7.44 ± 0.07 7.43 ± 0.06 7.41 ± 0.05
CTRL-GSNO 7.39 ± 0.10 7.39 ± 0.10 7.37 ± 0.10
CPB-PLAC 7.46 ± 0.08 7.43 ± 0.09 7.43 ± 0.09
CPB-GSNO 7.38 ± 0.08 7.43 ± 0.10 7.43 ± 0.09
CD18 expression (units)
CTRL-PLAC 30.3 ± 8.0 31.0 ± 10.8 33.6 ± 9.6
CTRL-GSNO 35.9 ± 14.2 39.2 ± 16.3 39.8 ± 15.1
CPB-PLAC 27.0 ± 8.1 27.5 ± 6.0 35.7 ± 9.3*
CPB-GSNO 25.6 ± 9.5 28.7 ± 10.0 26.8 ± 11.5
WBC, White blood cell corrected for hemodilution effect; CD18 expression,
mean fluorescent intensity of neutrophils for CD18 (see text). 
*Denotes a significant difference (P < .05) compared with other periods with-
in same group. 
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Results
Hemodynamics. Before GSNO infusion, systemic
arterial pressure was similar between the CTRL-GSNO
and CPB-GSNO groups (123 ± 13 mm Hg and 119 ± 19
mm Hg, respectively. To achieve a 10% reduction of
systemic arterial pressure, the total dose of GSNO
administered over the course of the study was 30 ± 7.0
mg and 34 ± 8.3 mg for the CTRL-GSNO and CPB-
GSNO groups, respectively. There were no differences
in hemodynamics (Table I) when the bypass-treated
groups were compared (CPB-GSNO with the CPB-
PLAC groups) or when the control groups were com-
pared (CTRL-GSNO with the CTRL-PLAC groups).
Values of systemic arterial pressure, systemic vascular
resistance, and cardiac output decreased over time in the
2 CPB-treated groups (baseline vs 4 hours after CPB; P
= .03). To achieve our predefined hemodynamic end
points (systemic arterial pressure > 60 mm Hg and right
atrial pressure < 15 mm Hg), the total vasoconstrictor
infusion rate was kept higher in the CPB-PLAC group
than in the CPB-GSNO group (3.1 ± 3.1 m g/min vs 0.2
± 0.4 m g/min, respectively; P = .05). More animals in
the CPB-PLAC group (4/6) received phenylephrine
than in the CPB-GSNO group (2/6). Total fluid admin-
istration was similar between the 2 CPB-treated groups
(1200 ± 488 mL vs 1475 ± 293 mL). 
CD18 expression in neutrophils. Table II shows
values of neutrophil cell surface expression of CD18,
hemoglobin, white blood cell counts, and arterial blood
gases. Significant hemodilution was observed in all
Fig 2. Mean ± SD values of Ca2+-dependent and Ca2+-independent NOS activity in placebo-treated animals.
Values are shown for left atrium (top), left ventricle (middle), and coronary artery (bottom). Asterisk (*) repre-
sents a significant difference (P < .05) between bypass (black bars) and control (white bars) groups. Note that
Ca2+-independent NOS activity is markedly increased in the bypass group. 
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groups throughout the study. After correcting for the
degree of hemodilution, the total white blood cell count
increased over time in all groups except the CRTL-
PLAC group. Neutrophils, as a percentage of white
blood cells, increased significantly over time in the
CPB-PLAC and CPB-GSNO groups from baseline to 4
hours after CPB (60% ± 13% to 77% ± 7%; P = .03;
and 69% ± 6% to 78% ± 7%; P < .04, respectively).
Concurrently, neutrophil mean fluorescence of CD18
increased from baseline levels to 4 hours after CPB in
the CBP-PLAC group (P = .03), whereas values of
mean fluorescence did not change significantly in the
CPB-GSNO group (P = .6). Similarly, in the 2 groups
that did not receive CPB, neutrophil numbers and
CD18 expression did not change over time.
Gas exchange. Values of PO2 (Table II) did not
change over time in the CTRL-GSNO and in the
CTRL-PLAC groups. After CPB, absolute values of
PO2 in the CPB-GSNO and CPB-PLAC groups were
similar. However, from baseline values to values mea-
sured 4 hours after CPB, PO2 decreased in the CPB-
PLAC group but increased in the CPB-GSNO group
(–188 ± 239 mm Hg vs +28 ± 140 mm Hg, respective-
ly; P = .04). Intrapulmonary shunt improved over the
same time by a mean value of 15.7% ± 14.5% in the
CPB-GSNO group compared with the CPB-PLAC
group (P = .05), which did not change over time (0.0%
± 14.3%). 
NOS activity. Fig 2 illustrates the effects of CPB on
Ca2+-dependent and Ca2+-independent NOS activities
in the left atrium, ventricle, and coronary artery. The
Ca2+-dependent NOS activities were similar between
the CTRL-PLAC and the CPB-PLAC groups, but the
Ca2+-independent NOS activities were significantly
higher (P = .005) in the CPB-PLAC group than in the
CTRL-PLAC group. Fig 3 shows the effects of GSNO
on the CPB-induced changes in Ca2+-independent NOS
activity. The administration of GSNO resulted in levels
of Ca2+-independent NOS that were significantly
decreased in samples from the ventricle (P = .001),
atrium (P = .01), and coronary artery (P = .005) when
compared with samples from the CPB-PLAC group.
The administration of GSNO to control animals did not
influence NOS activity (ie, CRTL-GSNO compared
with CTRL-PLAC). The Ca2+-dependent and -indepen-
dent NOS activities under these conditions were 6.1 ±
1.5 and 2.3 ± 1.1 pmol/min per milligram of protein,
respectively, in the CRTL-GSNO group.
Discussion
Model of CPB. The studies on the cardiovascular
effects of CPB are often confounded by the specific
surgical procedure used. Indeed, even during sham
bypass procedures that include sternotomy and reinfu-
sion of blood collecting in the mediastinum, there is
activation of inflammatory pathways.16 Therefore, in
these experiments, control animals were anesthetized
but not subjected to a sham bypass procedure. We have
attempted to reproduce human CPB in dogs, but there
are some important differences. The dogs, unlike
human beings, were not known to have underlying
heart disease before CPB. As well, the surgical expo-
sure was obtained via a thoracotomy rather than
through a sternal approach. Intraoperatively, bypass
grafting was not performed and, finally, an intra-aortic
catheter was used to occlude aortic flow instead of an
external aortic crossclamp. We also examined whether
nonspecific induction of iNOS occurred after thoraco-
tomy in 2 additional control animals, and we did not
find evidence of significant iNOS induction. In this
study we have not separated the possible role of atrial
line insertion on induction of iNOS. Similarly, we have
not controlled for the re-infusion of blood that collect-
ed within the mediastinum. Rather, these procedures
are integral parts of the entire process of CPB. If any-
thing, this study would underestimate the extent of
iNOS induction, since we attempted to minimize the
surgical trauma associated with the process of CPB. 
Bypass-induced activation of NOS. We have mea-
sured the activity of NOS in the myocardium and coro-
nary artery and found that CPB is associated with an
increase in the activity of Ca2+-independent NOS. This
Fig 3. The effects of GSNO administration on Ca2+-indepen-
dent NOS activity in the left atrium, left ventricle, and coro-
nary artery in bypass-treated animals. The Ca2+-independent
NOS activity is represented along the y axis. The solid bars
represent animals receiving bypass but treated with placebo.
The open bars represent animals receiving bypass and treat-
ed with GSNO. Note significant reductions in left atrial, left
ventricular, and coronary artery Ca2+-independent NOS
activity in the GSNO-treated animals.
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is in agreement with the work by Morita and col-
leagues,8,17 who found that CPB is associated with
increased generation of NO in plasma and myocardi-
um. In the heart, increased activity of Ca2+-independent
NOS correlates well with enhanced expression of
iNOS.18
Increased expression of iNOS with resultant overpro-
duction of NO is often mediated through pro-inflam-
matory cytokines such as tumor necrosis factor–a or
interleukin-1 b . Cytokines such as interleukin-1 b ,
tumor necrosis factor–a , and interleukin-6 are also
increased after CPB,6,19 and these pro-inflammatory
cytokines can also mediate increased NO production in
the heart.7 It is, therefore, possible that the generation
of cytokines mediates the expression of Ca2+-indepen-
dent NOS and contributes to the clinically observed
myocardial dysfunction associated with CPB.20,21
However, in our studies we did not measure cytokine
production; therefore their possible role remains spec-
ulative only. The early myocardial injury may be relat-
ed in part to increased neutrophil activation and adhe-
sion to the endothelium, reactions involving the
generation and release of cytokines. The expression of
neutrophil surface adhesion complexes is increased
after coronary artery bypass grafting,22 and treatment to
limit this effect16,23 can ameliorate CPB-induced
myocardial injury. We hypothesize that the CPB-
induced injury is caused by increased neutrophil acti-
vation leading to the release of pro-inflammatory
cytokines and excessive expression of NO and perox-
ynitrite (ONOO–). Peroxynitrite is a potent tissue-dam-
aging oxidant whose generation often accompanies the
expression of iNOS24 that can render the coronary cir-
culation nonreactive to vasodilators25 and impair
myocardial contractility.26
NO as a therapeutic target in CPB. If iNOS has a
pathogenic role in causing the cellular lesions after
CPB, then pharmacologic inhibition of iNOS expres-
sion or activity could be clinically beneficial. The
results of our study support this hypothesis. We have
found that GSNO administration resulted in improved
gas exchange, decreased vasopressor requirements, and
decreased activation of granulocytes. Moreover, GSNO
administration clearly decreased activity of Ca2+-inde-
pendent NOS. This down-regulation of iNOS expres-
sion has been shown in vitro,9,10 but so far as we are
aware, our study is the only in vivo confirmation of
these in vitro observations. 
We used changes in neutrophil fluorescence-activat-
ed cell sorter mean fluorescence for CD1822 as a surro-
gate for neutrophil activation and found that GSNO
administration limited the increase in leukocyte activa-
tion after CPB. NO donors have been shown to inhibit
granulocyte activation in vitro27 and to inhibit granulo-
cyte-endothelial interactions.28 Furthermore, direct
administration of NO gas through the oxygenator in an
animal model of CPB can reduce platelet adherence to
the membrane, as well as platelet aggregation.29
Inhibition of granulocyte activation limits organ
injury30 and thus any therapeutic effect of GSNO may
be at least partially dependent on inhibition of granulo-
cyte CD18 expression or on inhibition of platelet
aggregation. However, GSNO may influence other cel-
lular protective effects, and our study was not designed
to differentiate between various mechanisms. However,
some NO donors do not have similar cytoprotective
effects. In an in vitro model, GSNO has been shown to
reduce oxidative injury whereas 2 other NO donors,
sodium nitroprusside and SIN-1, have been shown to
worsen the injury.12 Thus our findings with GSNO can-
not be extrapolated to all other classes of NO donors.
We have also found that after CPB the placebo-treat-
ed animals required more vasoconstrictor than did the
GSNO-treated animals to maintain a mean blood pres-
sure of at least 60 mm Hg. We hypothesize that GSNO
reduced expression of inducible NO in the coronary
arteries and similarly reduced expression in the sys-
temic vasculature, thus explaining the limited require-
ment for vasoconstrictor therapy in CPB-GSNO ani-
mals. Although the reduction of excessive NO
production may have other benefits (eg, reduction of
peroxynitrite generation), our study was not designed
to answer this question, and any other clinical benefits
remain speculative. 
In summary, we have shown that CPB causes
increased activity of iNOS in the heart, an effect pre-
vented by GSNO. This effect may include the inhibi-
tion of granulocyte activation that underlies the CPB-
induced injury. Therefore NO donors such as GSNO
may represent a new class of compounds that improve
clinical outcomes after CPB or other forms of extra-
corporeal circulation.
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secretarial support. 
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